Corvia Medical Closes $55 Million Funding Round To Complete Confirmatory Trial And Pursue FDA Approval Of Corvia Atrial Shunt

Existing investors provide funding to finish international RESPONDER-HF trial

TEWKSBURY, Mass., June 17, 2025 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the successful closure of a $55 million funding round from the company's existing investment syndicate of Third Rock Ventures, General Catalyst Partners, AccelMed, Lumira Ventures, and two strategic investors.

The funds will be used to complete the ongoing RESPONDER-HF trial, a double-blinded, randomized, sham-controlled, confirmatory trial of the Corvia^® Atrial Shunt currently underway at more than 65 institutions on three continents. The study is expected to generate the final supportive clinical data required for FDA approval of the shunt as a breakthrough treatment for heart failure with preserved and mildly reduced ejection fraction (HFpEF/HFmrEF).

"We are profoundly grateful for the unwavering support of our longstanding investors as we advance toward FDA submission of the Corvia Atrial Shunt," said George Fazio, CEO of Corvia Medical. "Their commitment furthers our mission to bring this transformative heart failure treatment to millions of patients worldwide."

Paul LaViolette, Board Chair of Corvia Medical, added, "We firmly believe Corvia has the potential to fundamentally alter the landscape of heart failure treatment, and our investors share that vision. With these resources, we are well-equipped to drive the company through the approval process and introduce this groundbreaking therapy to the market."

About heart failure (HF) and the Corvia Atrial Shunt

More than 26 million people worldwide have HF, and the majority have HFpEF, making it the largest unmet clinical need in cardiovascular medicine. The Corvia Atrial Shunt is designed to reduce elevated left atrial pressure (LAP), the primary contributor to HF symptoms, by creating a passage between the left and right atria, reducing HF events and improving quality of life. The Corvia Atrial Shunt was granted Breakthrough Device designation by the FDA in 2019. For information regarding RESPONDER-HF study eligibility, please visit https://treatmyheartfailure.com.

About Corvia Medical, Inc.

Corvia Medical, Inc. is revolutionizing the treatment of heart failure through novel transcatheter cardiovascular devices. Founded in 2009 and headquartered in Tewksbury, MA, privately-held Corvia is dedicated to transforming the standard of care for heart failure treatment, enabling patients to reclaim their lives. Visit https://corviamedical.com.

MEDIA CONTACT:

Lisa Ensz

+1 978-654-6120

lensz@corviamedical.com

View original content:https://www.prnewswire.com/news-releases/corvia-medical-closes-55-million-funding-round-to-complete-confirmatory-trial-and-pursue-fda-approval-of-corvia-atrial-shunt-302483297.html

SOURCE Corvia Medical, Inc.

Frequently Asked Questions

What is the Corvia Atrial Shunt?

The Corvia Atrial Shunt is designed to reduce elevated left atrial pressure (LAP), the primary contributor to heart failure symptoms, by creating a passage between the left and right atria.

What is the RESPONDER-HF trial?

The RESPONDER-HF trial is a double-blinded, randomized, sham-controlled study of the Corvia Atrial Shunt, expected to generate the final clinical data required for FDA approval.

What type of heart failure does the Corvia Atrial Shunt target?

The Corvia Atrial Shunt targets heart failure with preserved and mildly reduced ejection fraction (HFpEF/HFmrEF).

First published on Tue, Jun 17, 2025

Enjoyed what you've read so far? Great news - there's more to explore!

Stay up to date with the latest news, a vast collection of tech articles including introductory guides, product reviews, trends and more, thought-provoking interviews, hottest AI blogs and entertaining tech memes.

Plus, get access to branded insights such as informative white papers, intriguing case studies, in-depth reports, enlightening videos and exciting events and webinars from industry-leading global brands.

Dive into TechDogs' treasure trove today and Know Your World of technology!

Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.

Tags:

Corvia Medical heart failure atrial shunt RESPONDER-HF trial FDA approval HFpEF HFmrEF cardiovascular medicine transcatheter devices

Join The Discussion

- Promoted By TechDogs -

Health Care Technology